Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Open Medicine

formerly Central European Journal of Medicine

Editor-in-Chief: Darzynkiewicz, Zbigniew


IMPACT FACTOR 2018: 1.221

CiteScore 2018: 1.01

SCImago Journal Rank (SJR) 2018: 0.329
Source Normalized Impact per Paper (SNIP) 2018: 0.479

ICV 2017: 152.94

Open Access
Online
ISSN
2391-5463
See all formats and pricing
More options …
Volume 12, Issue 1

Issues

Volume 10 (2015)

Tumor microenvironment in treatment of glioma

Guijie Li
  • Department of Otorhinolaryngology Head and Neck Surgery, China-Japan Union hospital of Jilin University, Changchun 130033, China
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Zhigang Qin
  • Department of Neurosurgery, China-Japan Union hospital of Jilin University, Changchun 130033,China
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Zhuo Chen
  • Department of Neurosurgery, China-Japan Union hospital of Jilin University, Changchun 130033,China
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Lijuan Xie
  • Department of Vascular Surgery, China-Japan Union hospital of Jilin University, Changchun 130033, China
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Ren Wang
  • Department of Neurosurgery, The People’s Hospital of Fusong County of Jilin Province, Fusong 134500, China
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Hang Zhao
  • Corresponding author
  • Department of Neurosurgery, China-Japan Union hospital of Jilin University, Changchun 130033,China
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2017-08-12 | DOI: https://doi.org/10.1515/med-2017-0035

Abstract

Glioma is one of the most malignant and fatal tumors in adults. Researchers and physicians endeavor to improve clinical efficacy towards it but made little achievement. In recent years, people have made advances in understanding characteristics and functions of tumor microenvironment and its role in different processes of tumor. In this paper, we describe the effects of tumor microenvironment on glioma proliferation, invasion and treatments. By explaining underlying mechanisms and enumerating new therapy strategies employing tumor microenvironment, we aim to provide novel ideas to improve clinical outcomes of glioma.

Keywords: Glioma; Tumor microenvironment; Treatment

1 Introduction

The occurrence, progress and invasion of tumor are closely related with the microenvironment surrounding the tumor, which is a network including various cell types, stroma, blood vessels, secreted factors, surrounding matrix and also inner environment of tumor cells. Tumor cells can change and maintain their ambience through autocrine and paracrine to promote their own proliferation and development. There exist mutual dependency, promotion, antagonism and fight between tumor and the environment. With recent achievements in oncocytology and molecular biology, we have got a deeper understanding on relationship of tumor and its microenvironment, which means a lot in study, diagnosis, treatment and prognosis of tumors. In immunotherapies for tumors, positive responds are usually depending on the interaction of tumor cells and immunoregulation in tumor microenvironment. Tumor microenvironment plays a crucial role in suppression or enhancement of immune response. A good understanding of tumor microenvironment and its mutual effects with tumor is important to more than reveal the mechanisms but also provide new strategies to improve efficacy of immunotherapies.

Glioma is one of the most common and aggressive primary tumors in adults. Despite improved insight into the underlying molecular mechanisms, it is still hard to be treated and the prognosis of patients remains poor due to fast progress and scarcity of effective treatment strategies. The highly heterogeneous tumor microenvironment plays a substantial role in tumor malignancy and treatment responses. It is also related with resistance of glioma cells to chemotherapy [1]. In this review, we summarized influences of tumor microenvironment on glioma cells behaviors, clinical efficacy and prognosis of glioma, revealed possible underlying mechanisms and shared some therapy strategies that utilizing characteristics of microenvironment to improve clinical outcomes [2-5].

2 Tumor microenvironment and glioma and related mechanisms

As the most abundant glial cells in glioma microenvironment, astrocytes significantly contribute to glioma pathogenesis. Activated astrocytes surround and infiltrate glioma cells and protect them from cytotoxic effects caused by various chemotherapeutic agents. As one of the major stromal cells in the brain, astrocytes are closely related to the malignant phenotype of gliomas, and they play important roles in chemo-resistance of gliomas. Recent studies showed that through direct contact with glioma cells and infiltrating around the tumor, astrocytes demonstrated protective effects for glioma against chemotherapeutic drugs, which might reveal the mechanism underlying the unsatisfactory clinical outcomes of chemotherapy [6, 7]. The gap junctional communication (GJC) between glioma cells and astrocytes has presented protective effect via expression levels regulation of various critical survival genes by astrocytes. That result indicated that the microenvironment may affect the behavior of tumor cells and might be related with resistance in glioma cells [8]. Astrocytes could increase the secretion of IL-6 and induce the expression of membrane type 1 matrix metalloproteinase (MMP14), and thus enhance the migration and invasion of gliomas, which is a proof of influence of microenvironment on tumor processes [9]. A syngeneic model of glioma resection and recurrence in mice was developed and influences of surgical resection on glioma biology and the local microenvironment were examined. Results demonstrated that resection-induced injury led to alterations in reactive astrocytes in the peritumoral microenvironment and astrocyte injury induced changes in transcriptome and secretome as well as promotion of tumor proliferation and migration. That indicates a necessity of further knowledge of the postsurgical tumor microenvironment for targeted anticancer agents development [10].

Myeloid-derived suppressor cells (MDSCs) constitute >40% of the infiltrating immune cells and can accumulate to induce immunosuppression in glioma. MDSCs can also secret many kinds of cytokines that are involved in antigen-specific T cell suppression. Researchers demonstrated that depletion or blockade of MDSCs augment the efficacy of immunotherapy, which presented promise for increasing the efficacy of immunotherapies for glioma [11]. Within the glioma microenvironment, macrophages and microglia could produce CCL2, which is critical for recruiting MDSCs and regulatory T cells (Treg). In clinical specimens of glioma, enhanced expression of CCL2 is related with reduced overall survival. This is another proof of how tumor microenvironment induces immunosuppression and drive glioma progression [12].

Heparanase (HPSE), which cleaves Heparan sulfate proteoglycans (HSPG), breaks down modified sugar chains on cell surfaces as well as in the extracellular space. Its level is positively correlated with tumor development in the brain. Tumor microenvironment, reactive astrocytes, microglia/monocytes and tumor angiogenesis are also influenced by HPSE. HPSE is highly expressed in glioma and inhibition of HPSE reduces glioma cell numbers. Furthermore, high levels of HPSE appeared to be related with shorter survival in patients with highgrade glioma. These data provide proof for anti-HPSE treatment of glioma [13].

B7-H4 (B7x/B7S1) is a B7 family member whose expression in tumors was associated with prognosis malignant grades of glioma. Silencing of B7-H4 expression in glioma and microenvironment supporting cells lead to increased microenvironment T-cell function and tumor inhibition, which made it an important immunosuppressive event holding back effective T-cell immune responses and a potential therapy target [14].

Tumor microenvironment can also drive resistance to inhibition of colony-stimulating factor-1 receptor (CSF-1R), which targets macrophages accumulate in glioma progression. Mechanisms of this effect conclude IGF-1 induced phosphatidylinositol 3-kinase (PI3K) pathway activity [15].

EGFR amplification and mutation, especially EGFRvIII are the mostly found signatures in glioma. Researchers demonstrated that hypoxia tumor microenvironment and ECM vitronectin could enhance tumor cell invasion and EGFRvIII activity through EGFRvIII and integrin β3 complex, emphasizing key roles of tumor microenvironment in tumor progression and metastasis [16].

Extracellular matrix tenascin-C (TNC) consist the brain tumor microenvironment. Studies show that decreased TNC leads to tumor invasion reduction and tumor proliferation increase, which means that tumor microenvironment, modulates stromal cells behaviors and influences tumor behavior as well [17].

Ca2+-activated K+ channel (KCa3.1) is expressed in both glioma and infiltrating microglia/macrophages (M/MΦ) and is involved in glioma progress promotion under mechanisms including FAK and PI3K/AKT. Inhibition of KCa3.1 would lead to a switch of M/MΦ cells toward a pro-inflammatory, antitumor phenotype and contribute to glioma development reduction, suggesting a possible role for KCa3.1 as a therapeutic target in glioma [18].

As an important gap junction protein in astrocytes, connexin43 (Cx43) is over-expressed in glioma-associated astrocytes at the peri-tumoral region. Cx43 increases malignancy in tumor cells through mediating intercellular communication. And expression of Cx43 is related with glioma cells dissemination from the tumor core by manipulating the microenvironment [19].

A study has proved that tumor microenvironment can facilitate malignant transformation of bone marrow stromal cells (BMSCs) into glioma cancer stem cells (CSCs) [20].

Exosomes are one type of extracellular vesicles (EVs), which mediate intercellular communication for normal and tumor cells as well. Exosomes secreted by tumor cells take parts in different tumor processes and modify tumor microenvironment for progression. The roles exosomes play in cross-talk within tumor microenvironment and intercellular communication make them tumor biomarkers and a potential therapeutic target/delivery system [21].

3 New therapy strategies

3.1 Drug delivery system

Advances have been achieved in active targeting drug delivery system (DDS) in glioma diagnosis and therapy. Lack of sufficient targets on glioma cells and limited penetration capability of DDS significantly compromise the treatment efficacy. So it is important to explore effective receptor targets. Researchers constructed dual-decorated nanoparticulate DDS loaded with paclitaxel (PTX). By taking advantages of the tumor microenvironment dual-targeting and angiogenic blood vessels effect, this DDS extensively accumulated at glioma site and resulted in improved anti-glioma efficacy with enhanced penetration capability in vivo, which made it a promising drug delivery method in glioma treatment [22].

In another research, nanoparticles (NPs) were related with a substrate of large amino acid transporter 1 (LAT1) that is overexpressed in both blood-brain-barrier and glioma cells. And as levels of adenosine-5’-triphosphate (ATP) and glutathione (GSH) are remarkably diverse between extracellular and intracellular milieu, the doxorubicin (DOX)-conjungated NPs were designed to be targeting both ATP&GSH. Results showed that both enhanced NP accumulation and rapid DOX release in glioma were demonstrated, with more efficient therapeutic effects and no systemic toxicity observed. This study proved the feasibility of GSH & ATP dual-responsive utilizing microenvironment strategy to improve efficacy of chemotherapy for glioma [23].

Based on the cognition that the pH environment in gliomas is acidic, people constructed pH-sensitive liposomes with DOX encapsulated in them. Responding to the acidic pH in glioma, a specific targeting drug release was observed. Anti-tumor activity of the liposomes was also demonstrated in the in vivo experiment, which made those particles one of the drug delivery systems that are suitable for targeting anti-tumor therapy [24].

In a study, a delivery system based on gold nanoparticle was developed. The nanoparticles loading DOX were coated with PEG. Results showed that the release of DOX was pH-dependent and cellular uptake as well as glioma distribution were both at a higher intensity. Longer median survival time was also acquired in glioma-bearing mice, making these nanoparticles a feasible drug delivery system [25].

PEG-PLA nanoparticles were designed to target fibronectins (FNs), which is a prevailing component in the abundant extracellular matrix (ECM). ECM is abundant in the glioma microenvironment and play a critical role in different tumor progresses. This FN-targeting drug delivery system loaded with paclitaxel demonstrated favored penetration into glioma spheroids and significant proliferation inhibitive effects as well as prolonged survival time, proving that ECM could be a potential target for drug delivery in clinical applications [26].

3.2 Viroimmunotherapy

Vesicular stomatitis virus (VSV) expressing a complementary cDNA library is applicated in tumors treatments by vaccinating against tumor associated antigens (TAAs). This systemic viroimmunotherapy consisting of histological type-specific antigens and location-specific antigens against gliomas achieved satisfying immune responses, which could be enhanced by immune checkpoint inhibitors. That indicates that VSV-TAA therapy, combined with checkpoint inhibition, has got clinical values, as well as the importance of the tumor microenvironment in immunotherapy [27].

In an intratumoral virotherapy research, an oncolytic adenovirus was administrated intratumorally. Decreased tumor-infiltrating Tregs and increased IFNγ-producing CD8+ T cells was observed, even in highly immunosuppressive tumor microenvironment in late stage diseases. Additionally, this treatment could enhance systemically transferred tumor-antigen-specific T cell therapy and reprogram immunosuppressive Tregs to a stimulatory state [28].

In one study, adoptive immunotherapy with transferred antigen-specific T cells is adopted. Researchers combined systemic injection of bacterial lipoprotein (BLP), a TLR1/2 agonist, with that therapy. BLP could maintain T cell persistence, modify the tumor microenvironment and even induce systemic anti-tumor immunity and thus improve the adoptive T cell therapy, which might offer a strategy to overcome the obstacles for immunotherapy for glioma [29].

3.3 Antiangiogenic therapy

Antiangiogenic therapy added to immunotherapeutic approaches towards glioma has achieved clinical benefits, among which the endogenous microenvironment or vaccine-induced inflammatory responses is importantly subsidiary to its effectiveness. An inhibitor of vascular endothelial growth factor, aflibercept, was applied in combination with an antitumor vaccine. Delayed tumor progression and survival extension were observed, which confirmed the efficacy of combining antiangiogenic and immunotherapy approaches as well as the value of delineating tumor microenvironment [30].

Sunitinib, a small molecule with known anti-angiogenic effect, was found to induce glioma cell death by targeting VEGFR2 while protecting neurons and astrocytes. Sunitinib could normalize the tumor-derived aberrant vasculature and reduce tumor vessel pathologies multitargeted receptor tyrosine kinase inhibitor, on constituents of the tumor microenvironment such as gliomas, astrocytes, endothelial cells, and neurons. Sunitinib has a. We found that sunitinib normalizes the aberrant tumor-derived vasculature, reduces tumor vessel pathologies, and alleviate tumor-induced neurodegeneration. Furthermore, when combined with temozolomide, sunitinib could amplify the effects of temozolomide on glioma cells, of which the researchers thought to be related with influences of sunitinib on the brain tumor microenvironment [31].

Anti-angiogenic molecules combined with autophagy inhibitor have been proved effective in treating gliomas in vivo. Hypoxia could augment this potency possibly through stimulation of autophagosome, which is prevalent in the glioma microenvironment and late stage autophagy inhibitor may act by drive cytotoxic autophagic vacuole accumulation that is cytotoxic towards glioma cells [32].

4 Conclusion

Tumor microenvironment is a double-edged sword in occurrence, treatment and prognosis of glioma. Tumor cells can adjust its neighborhood to facilitate its own progress and microenvironment can contribute to proliferation, invasion and drug-resistance of glioma. But on the other side, targeting tumor environment may improve infiltration and efficacy of chemical agents and assist immunotherapy to take effect. All above indicate importance to further explore mechanisms related with tumor environment and make these understanding helpful to clinical treatments.

References

  • [1]

    Zinnhardt B, Pigeon H, Theze B, Viel T, Wachsmuth L, Fricke IB, et al. Combined PET imaging of the inflammatory tumor microenvironment identifies margins of unique radiotracer uptake. Cancer research. 2017 PubMedWeb of ScienceGoogle Scholar

  • [2]

    Jansen F, van Zwieten V, Coupe VM, Leemans CR, Verdonck-de Leeuw IM. A Review on Cost-Effectiveness and Cost-Utility of Psychosocial Care in Cancer Patients. Asia-Pacific journal of oncology nursing. 2016;3(2):125-136 Web of SciencePubMedGoogle Scholar

  • [3]

    Eaton EB, Jr., Varney TR. Mesenchymal stem cell therapy for acute radiation syndrome: innovative medical approaches in military medicine. Military Medical Research. 2015;2:2CrossrefPubMedWeb of ScienceGoogle Scholar

  • [4]

    Yoshida K, Sulaiman NS, Miyawaki D, Ejima Y, Nishimura H, Ishihara T, et al. Radiotherapy for brainstem gliomas in children and adults: A single-institution experience and literature review. Asia-Pacific journal of clinical oncology. 2017;13(2):e153-e60Google Scholar

  • [5]

    Kanou T, Okami J, Tokunaga T, Ishida D, Kuno H, Higashiyama M. Prognostic factors in patients with postoperative brain recurrence from completely resected non-small cell lung cancer. Thoracic cancer. 2015;6(1):38-42 CrossrefWeb of SciencePubMedGoogle Scholar

  • [6]

    Irvin DM, McNeill RS, Bash RE, Miller CR. Intrinsic Astrocyte Heterogeneity Influences Tumor Growth in Glioma Mouse Models. Brain pathology. 2017;27(1):36-50 Web of ScienceCrossrefGoogle Scholar

  • [7]

    Chen W, Wang D, Du X, He Y, Chen S, Shao Q, et al. Glioma cells escaped from cytotoxicity of temozolomide and vincristine by communicating with human astrocytes. Medical oncology. 2015;32(3):43 CrossrefWeb of ScienceGoogle Scholar

  • [8]

    Lin Q, Liu Z, Ling F, Xu G. Astrocytes protect glioma cells from chemotherapy and upregulate survival genes via gap junctional communication. Molecular medicine reports. 2016;13(2):1329-1335 CrossrefPubMedWeb of ScienceGoogle Scholar

  • [9]

    Chen W, Xia T, Wang D, Huang B, Zhao P, Wang J, et al. Human astrocytes secrete IL-6 to promote glioma migration and invasion through upregulation of cytomembrane MMP14. Oncotarget. 2016;7(38):62425-62438 PubMedWeb of ScienceGoogle Scholar

  • [10]

    Okolie O, Bago JR, Schmid RS, Irvin DM, Bash RE, Miller CR, et al. Reactive astrocytes potentiate tumor aggressiveness in a murine glioma resection and recurrence model. Neuro-oncology. 2016;18(12):1622-1633 CrossrefGoogle Scholar

  • [11]

    Kamran N, Kadiyala P, Saxena M, Candolfi M, Li Y, Moreno-Ayala MA, et al. Immunosuppressive Myeloid Cells’ Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy. Molecular therapy: the journal of the American Society of Gene Therapy. 2017;25(1):232-248 CrossrefPubMedGoogle Scholar

  • [12]

    Chang AL, Miska J, Wainwright DA, Dey M, Rivetta CV, Yu D, et al. CCL2 Produced by the Glioma Microenvironment Is Essential for the Recruitment of Regulatory T Cells and Myeloid-Derived Suppressor Cells. Cancer research. 2016;76(19):5671-5682 Web of ScienceCrossrefPubMedGoogle Scholar

  • [13]

    Kundu S, Xiong A, Spyrou A, Wicher G, Marinescu VD, Edqvist PD, et al. Heparanase Promotes Glioma Progression and Is Inversely Correlated with Patient Survival. Molecular cancer research : MCR. 2016;14(12):1243-1253 CrossrefPubMedGoogle Scholar

  • [14]

    Yao Y, Ye H, Qi Z, Mo L, Yue Q, Baral A, et al. B7-H4(B7x)- Mediated Cross-talk between Glioma-Initiating Cells and Macrophages via the IL6/JAK/STAT3 Pathway Lead to Poor Prognosis in Glioma Patients. Clinical cancer research: an official journal of the American Association for Cancer Research. 2016;22(11):2778-2790 PubMedCrossrefGoogle Scholar

  • [15]

    Quail DF, Bowman RL, Akkari L, Quick ML, Schuhmacher AJ, Huse JT, et al. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science. 2016;352(6288):aad3018 PubMedCrossrefWeb of ScienceGoogle Scholar

  • [16]

    Liu Z, Han L, Dong Y, Tan Y, Li Y, Zhao M, et al. EGFRvIII/ integrin beta3 interaction in hypoxic and vitronectinenriching microenvironment promote GBM progression and metastasis. Oncotarget. 2016;7(4):4680-4694 PubMedGoogle Scholar

  • [17]

    Xia S, Lal B, Tung B, Wang S, Goodwin CR, Laterra J. Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation. Neuro-oncology. 2016;18(4):507-517 Web of SciencePubMedCrossrefGoogle Scholar

  • [18]

    Grimaldi A, D’Alessandro G, Golia MT, Grossinger EM, Di Angelantonio S, Ragozzino D, et al. KCa3.1 inhibition switches the phenotype of glioma-infiltrating microglia/macrophages. Cell death & disease. 2016;7:e2174 Web of ScienceCrossrefPubMedGoogle Scholar

  • [19]

    Sin WC, Aftab Q, Bechberger JF, Leung JH, Chen H, Naus CC. Astrocytes promote glioma invasion via the gap junction protein connexin43. Oncogene. 2016;35(12):1504-1516 CrossrefWeb of SciencePubMedGoogle Scholar

  • [20]

    He Q, Zou X, Duan D, Liu Y, Xu Q. Malignant transformation of bone marrow stromal cells induced by the brain glioma niche in rats. Molecular and cellular biochemistry. 2016;412(1-2):1-10 Web of SciencePubMedCrossrefGoogle Scholar

  • [21]

    Gourlay J, Morokoff AP, Luwor RB, Zhu HJ, Kaye AH, Stylli SS. The emergent role of exosomes in glioma. Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia. 2017;35:13-23 CrossrefPubMedGoogle Scholar

  • [22]

    Hu Q, Kang T, Feng J, Zhu Q, Jiang T, Yao J, et al. Tumor Microenvironment and Angiogenic Blood Vessels Dual-Targeting for Enhanced Anti-Glioma Therapy. ACS applied materials & interfaces. 2016;8(36):23568-23579 PubMedWeb of ScienceCrossrefGoogle Scholar

  • [23]

    An S, Lu X, Zhao W, Sun T, Zhang Y, Lu Y, et al. Amino Acid Metabolism Abnormity and Microenvironment Variation Mediated Targeting and Controlled Glioma Chemotherapy. Small. 2016;12(40):5633-5645 CrossrefWeb of SciencePubMedGoogle Scholar

  • [24]

    Zhao Y, Ren W, Zhong T, Zhang S, Huang D, Guo Y, et al. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity. Journal of controlled release: official journal of the Controlled Release Society. 2016;222:56-66 CrossrefPubMedGoogle Scholar

  • [25]

    Ruan S, Yuan M, Zhang L, Hu G, Chen J, Cun X, et al. Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles. Biomaterials. 2015;37:425-435 PubMedWeb of ScienceCrossrefGoogle Scholar

  • [26]

    Zhang B, Shen S, Liao Z, Shi W, Wang Y, Zhao J, et al. Targeting fibronectins of glioma extracellular matrix by CLT1 peptide-conjugated nanoparticles. Biomaterials. 2014;35(13):4088-4098 CrossrefWeb of SciencePubMedGoogle Scholar

  • [27]

    27. Cockle JV, Rajani K, Zaidi S, Kottke T, Thompson J, Diaz RM, et al. Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. Neuro-oncology. 2016;18(4):518-527 PubMedCrossrefWeb of ScienceGoogle Scholar

  • [28]

    Qiao J, Dey M, Chang AL, Kim JW, Miska J, Ling A, et al. Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy. Oncoimmunology. 2015;4(8):e1022302 CrossrefWeb of SciencePubMedGoogle Scholar

  • [29]

    Zhang Y, Luo F, Li A, Qian J, Yao Z, Feng X, et al. Systemic injection of TLR1/2 agonist improves adoptive antigen-specific T cell therapy in glioma-bearing mice. Clinical immunology. 2014;154(1):26-36 CrossrefWeb of ScienceGoogle Scholar

  • [30]

    Renner DN, Malo CS, Jin F, Parney IF, Pavelko KD, Johnson AJ. Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2016;13(1):226-236 CrossrefPubMedGoogle Scholar

  • [31]

    Hatipoglu G, Hock SW, Weiss R, Fan Z, Sehm T, Ghoochani A, et al. Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment. Cancer science. 2015;106(2):160-170 PubMedCrossrefWeb of ScienceGoogle Scholar

  • [32]

    Lobo MR, Wang X, Gillespie GY, Woltjer RL, Pike MM. Combined efficacy of cediranib and quinacrine in glioma is enhanced by hypoxia and causally linked to autophagic vacuole accumulation. PloS one. 2014;9(12):e114110 PubMedCrossrefWeb of ScienceGoogle Scholar

About the article

Received: 2017-03-26

Accepted: 2017-04-15

Published Online: 2017-08-12


Conflict of interestConflict of interest statement: Authors state no conflict of interest


Citation Information: Open Medicine, Volume 12, Issue 1, Pages 247–251, ISSN (Online) 2391-5463, DOI: https://doi.org/10.1515/med-2017-0035.

Export Citation

© 2017 Guijie Li et al.. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. BY-NC-ND 3.0

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Cristiana Angelucci, Gina Lama, and Gigliola Sica
International Journal of Molecular Sciences, 2019, Volume 20, Number 9, Page 2144
[2]
Ryte Rynkeviciene, Julija Simiene, Egle Strainiene, Vaidotas Stankevicius, Jurgita Usinskiene, Edita Miseikyte Kaubriene, Ingrida Meskinyte, Jonas Cicenas, and Kestutis Suziedelis
Cancers, 2018, Volume 11, Number 1, Page 17
[3]
Martina Da Ros, Veronica De Gregorio, Anna Iorio, Laura Giunti, Milena Guidi, Maurizio de Martino, Lorenzo Genitori, and Iacopo Sardi
International Journal of Molecular Sciences, 2018, Volume 19, Number 10, Page 2879
[4]
Ivana Manini, Federica Caponnetto, Anna Bartolini, Tamara Ius, Laura Mariuzzi, Carla Di Loreto, Antonio Beltrami, and Daniela Cesselli
International Journal of Molecular Sciences, 2018, Volume 19, Number 1, Page 147

Comments (0)

Please log in or register to comment.
Log in